GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Forward PE Ratio

Vanda Pharmaceuticals (FRA:VM4) Forward PE Ratio : 0.00 (As of May. 20, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Forward PE Ratio?

Vanda Pharmaceuticals's Forward PE Ratio for today is 0.00.

Vanda Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Vanda Pharmaceuticals's PE Ratio for today is 0.00.


Vanda Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Vanda Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Forward PE Ratio Chart

Vanda Pharmaceuticals Annual Data
Trend 2016-10 2017-12 2018-12 2019-12 2020-05
Forward PE Ratio
13.85 151.52 58.14 34.72 29.50

Vanda Pharmaceuticals Quarterly Data
2016-03 2016-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03
Forward PE Ratio 8.48 13.76 175.44 151.52 151.52 69.93 51.81 58.14 36.90 113.64 45.05 34.72 23.98

Competitive Comparison of Vanda Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Vanda Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Forward PE Ratio falls into.



Vanda Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Vanda Pharmaceuticals  (FRA:VM4) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Vanda Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (FRA:VM4) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines